OptimizeRx authorizes $20 million – GuruFocus.com

ROCHESTER, Mich., May 17, 2022 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (OPRX), a leading provider of point-of-care technology solutions that help patients begin and maintain treatment, today announced that its Board of Directors has authorized the unanimity a stock repurchase program, under which OptimizeRx can repurchase up to $20 million of its outstanding common stock.

Will Febbo, CEO of OptimizeRx, said, “The buyout approval reflects our focus on disciplined capital allocation strategies to drive shareholder returns. The share buyback program highlights the belief that our Board of Directors has in our company’s outlook, financial strength, industry positioning and commitment to creating value for our various stakeholders. .

“We intend to opportunistically repurchase our common stock, while maintaining strong working capital to fuel our future growth. We will continue to focus on both organic growth and M&A activity and believe we have enough cash to do both,” Febbo concluded.

About OptimizeRx
OptimizeRx is a best-in-class health technology company enabling care-driven engagement between life science organizations, healthcare providers, and patients at critical times throughout the patient care journey. patients. Connecting more than 60% of US healthcare providers and millions of their patients through the smartest technology platform integrated into a proprietary digital point-of-care network, OptimizeRx helps patients start and stay on their medications.

For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.

Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “expects”, “has intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify such forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy and other future conditions. These statements are neither promises nor guarantees and involve risks and uncertainties, some of which cannot be predicted or quantified. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. Future events and actual results could differ materially from those set forth, contemplated or implied by, or underlying the forward-looking statements, including, without limitation, risks relating to the Company’s ability to work and make appropriate, timely and beneficial decisions as to when, how and whether to purchase shares under the buyback program. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, its subsequent quarterly reports on Form 10-Q and its other filings with the Securities and Exchange Commission.

Contact OptimiserRx
Andy D’Silva, Senior Vice President of Corporate Finance
[email protected]

Media Relations
Maira Alejandra, Media Relations Manager
[email protected]

Investor Relations
Ashley Robinson
LifeSci Advisors, LLC
[email protected]

OptimizeRx-Corporation.png